Elusa Health

Overview

Elusa Health is the current operating identity for COPILOT Provider Support Services, a hub services and patient access platform for specialty therapies. It is most relevant to manufacturer teams that need benefits verification, prior authorization support, reimbursement workflows, affordability coordination, and patient support around complex access journeys.

The public buyer read is straightforward: Elusa is a hub and access-services partner, not a PBM or broad payer-side utilization-management platform. Its value proposition sits where provider offices, payers, patients, and manufacturer programs need coordinated eBV, ePA, reimbursement, and case escalation.

Hub Capability Model

The framework below standardizes how Rx Almanac evaluates hub-services capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Elusa is evaluated as an access-services hub focused on eBV, ePA, reimbursement workflow, and case escalation.

Capability	Buyer should compare	Elusa readout
Therapy initiation and enrollment intake	Digital and human intake, eConsent, missing-information resolution, provider/patient portals, and clean case creation.	Patient access operations. Elusa combines automation with human support for case management, provider-office support, patient outreach, bridge workflows, and exception handling; confirm enrollment-channel depth in RFP.
Benefits verification and coverage triage	Medical/pharmacy benefit verification, eligibility checks, payer-policy lookup, coverage routing, and speed from referral to actionable case.	Core. Elusa / COPILOT materials center on benefit verification, payer coverage, benefit-detail quality, and handoff into access workflows.
Prior authorization, appeals, and reimbursement casework	PA initiation, payer-specific forms, clinical documentation, appeals, denial management, and field reimbursement handoffs.	Core. AUTOPILOT is positioned as an eBV and ePA platform; validate Surescripts connectivity, documentation support, escalation rules, and appeals depth.
Affordability, PAP, and copay operations	Copay, free-drug, bridge, foundation, income verification, PAP renewal, and gross-to-net sensitive affordability logic.	Affordability operations. Copay, foundation, PAP, and affordability-program routing are relevant; buyers should validate program design, accumulator handling, and reporting.
Patient engagement and adherence operations	Omnichannel reminders, clinical education, nursing or training escalation, persistence outreach, and patient-facing support quality.	Access-support adjacency. Patient outreach is part of the access workflow, but clinical adherence, training escalation, and persistence programs should be scoped explicitly.
Fulfillment, specialty pharmacy, and distribution coordination	Routing to SPs, non-commercial dispensing, DTP shipment, sample/replacement product, 3PL, and cold-chain handoffs.	Partner-boundary diligence. Elusa is a hub and access-services partner, not a dispensing pharmacy or 3PL; define handoffs to specialty pharmacies and fulfillment partners.
Program reporting, integrations, and governance	Manufacturer dashboards, KPI reporting, CRM/EHR/API integrations, SLA governance, and operating visibility across vendors.	Confirm reporting layer. Reporting should cover program status, time-to-therapy, PA outcomes, abandonment, unresolved barriers, privacy controls, and integration responsibilities.

Buyer Fit

• Buyer trigger: Include Elusa when a specialty brand needs a technology-enabled hub focused on access, reimbursement, and provider-office workflows.
• Strong fit: Rare disease, orphan-drug, biologic, and other specialty therapies where eBV, ePA, reimbursement support, and case escalation affect speed to therapy.
• Manufacturer use case: Use Elusa to coordinate provider-facing reimbursement work, automate routine eBV / ePA steps, route affordability support, and report access bottlenecks.
• Less natural fit: A pure pharmacy-benefit ePA network buy, a standalone copay processor RFP, or a broad outsourced commercialization program where hub services are only one component.
• Commercial fit: Expect custom scoping around program design, call-center model, automation boundaries, privacy terms, reporting, and integration with specialty pharmacy and field reimbursement workflows.

Differentiators

• COPILOT continuity: Elusa is the successor brand to COPILOT Provider Support Services, retaining the legacy hub and reimbursement-services search intent.
• AUTOPILOT platform: The platform gives the profile a clearer technology angle than a call-center-only hub provider.
• Explicit manufacturer fit: Public investor and company materials describe support for pharmaceutical-company partnerships and specialty therapy access.
• Access-first positioning: The 2026 rebrand frames the company around clarity, access, and reducing administrative friction in therapy starts.
• Focused profile: Elusa reads as a specialist hub / reimbursement platform rather than a distributor-owned or full-stack commercialization vendor.

RFP Questions

• Which drug launches, therapeutic areas, and case volumes can Elusa reference under NDA?
• Which eBV and ePA workflows are automated, and which require manual case-manager intervention?
• How does AUTOPILOT connect to Surescripts, payer portals, hub CRMs, specialty pharmacies, and manufacturer reporting systems?
• What are the standard time-to-benefit-verification, time-to-PA-submission, and time-to-resolution benchmarks?
• How are copay, foundation, PAP, and bridge referrals routed and tracked?
• What current HIPAA, SOC, HITRUST, breach-notification, audit, and subcontractor controls are in place?
• How are patient consent, data sharing, and de-identification handled for manufacturer reports?
• How does Elusa staff launch surges, high-touch escalations, and provider-office support?

Recent Activity

• 2026: COPILOT Provider Services rebranded as Elusa Health.
• 2023: COPILOT announced Surescripts certification for electronic prior authorization services and described AUTOPILOT as its proprietary eBV / ePA platform.
• 2023: QHP Capital announced an investment in COPILOT Provider Support Services to support growth and capability expansion.